Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL32689764 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL21957852 | 0.83 | — | — | |
| L-Lactic Acid SCHEMBL31675123 | 0.83 | — | — | |
| L-Lactic Acid SCHEMBL14122584 | 0.83 | — | — | |
| L-Lactic Acid SCHEMBL2338870 | 0.81 | — | — | |
| SCHEMBL16945371 | 0.80 | — | — | |
| SCHEMBL10791333 | 0.80 | — | — | |
| Methylmalonic Acid SCHEMBL14590355 | 0.77 | — | — | |
| Cadaverine Tartrate SCHEMBL30804356 | 0.75 | TSHR (0.50) | — | |
| D-Lactic Acid SCHEMBL4371722 | 0.75 | TP53 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659754-A1 | USE OF LITHIUM-CONTAINING COMPOUNDS IN TREATMENT OF TUMORS | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-20250276008-A1 | USE OF LITHIUM-CONTAINING COMPOUNDS IN TREATMENT OF TUMORS | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-09-04 | — | — | US | disclosed |
| US-20250073234-A1 | COMBINATION THERAPIES INCLUDING PARP1 INHIBITORS | CORNELL UNIVERSITY | 2025-03-06 | — | — | US | disclosed |
| WO-2024159680-A1 | USE OF LITHIUM-CONTAINING COMPOUNDS IN TREATMENT OF TUMORS | 中国医学科学院基础医学研究所 | 2024-08-08 | — | — | WO | disclosed |
| US-20230255997-A1 | Ketogenic Diet and Ketone Supplementation for Cancer Therapy | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-08-17 | — | — | US | disclosed |
| WO-2023133409-A2 | COMBINATION THERAPIES INCLUDING PARP1 INHIBITORS | CORNELL UNIVERSITY (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-4181914-A2 | KETOGENIC DIET AND KETONE SUPPLEMENTATION FOR CANCER THERAPY | The Trustees of Princeton University (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20130052141-A1 | HYPERPOLARIZED LACTATE CONTRAST AGENT FOR DETERMINATION OF LDH ACTIVITY | GE HEALTHCARE LIMITED (GB) | 2013-02-28 | — | — | US | disclosed |